Business Wire

JAPAN-SANITARY-EQUIP-IND

Share
The Japan Sanitary Equipment Industry Association: Warm Water Spray Seat Shipments Reach 100 Million Units in Japan

The Japan Sanitary Equipment Industry Association, which is composed of Japanese companies engaged in the manufacturing of toilets (Headquarters: Nagoya, Aichi, Japan. President: Noriaki Kiyota [President & Representative Director of TOTO Ltd.], hereinafter “Association”) is proud to announce that the number of warm water spray seat shipments since the industry began tracking statistics (1987) has reached 100 million units as of June 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005331/en/

The Road to 100 Million Units

The start of importation and sale of toilets and toilet seats with warm-water washing functionality into Japan in 1964 sparked major changes of “washing bottoms” in Japanese toilets. At first, sales were targeted towards medical facilities, and use was not widespread. Later, domestic production began, and companies launched initiatives including product development and improvement, and sales promotions to encourage use in common households. Eventually, more Japan residents grew to recognize these products after a TV commercial in 1982. Once people experienced the comfort of a warm toilet seat and the refreshing satisfaction of rear cleansing, they were unable to live without it. Good reputations spread, and these products finally became accepted by the general public.

Association member companies have been working continuously to evolve these products and to promote further use, by making new proposals and implementing updates that reflect consumer needs across multiple aspects, including function, comfort, hygiene, design, and energy efficiency. Currently in 2022, usage rates in general households have surpassed 80%, which means that it can finally be said that these products are estimated to be used in the majority of general households with flushable toilets. Likewise, because warm water spray seats have a good reputation for comfort, they have also been widely adopted for use in public places such as office buildings, commercial facilities, hotels, trains, and train stations.

Must-Have Item for Japanese Bathrooms

According to an awareness survey conducted by the Association in 2022 among warm water spray seat users in Japan, the main reason for use was “It’s sanitary and feels good to use.” In addition, 97% of the respondents would like to continue to use the warm-water washing toilet seats, indicating that once they use them, they find it so comfortable that they will not want to give them up.

Meanwhile, outside of Japan, demands are growing in other countries across the Americas, Europe, Asia, and the Middle East in recent years as interest in hygiene continues to rise, and the international market for warm water spray seats continues to expand every year. In particular, a sudden rise in demand was seen in North America in 2020, stoking anticipation for wider usage in the near future.

The Association and its members, Japanese manufacturers of warm water spray seats, are dedicated to making real improvements in restroom culture worldwide through the wider usage of sanitary and comfortable warm water spray seats in every country.

Awareness Survey for Warm Water Spray Seat Users

Survey Method: Online questionnaire
Survey Targets: Users of warm-water washing toilet seats, aged 10 to 79, living in Japan, 150 respondents for each age group, total of 2,100 respondents
Survey Period: February 4, 2022 (Friday) to February 7, 2022 (Sunday)

[ Survey Results Summary ]

The main reason for use was “It’s sanitary and feels good to use.”
When asked why they use warm water spray seats, most respondents said “It removes waste well and keeps me clean” (82%) and nearly half of respondents said “It feels good and refreshing” (48%).

97% of respondents said “I want to continue using it.”
Regarding their intention to continue the use of warm-water toilet seats in the future, 86% of respondents said they would like to continue to use them, and 11% said they would rather continue to use them.

Learn More About the Japan Sanitary Equipment Industry Association

The Japan Sanitary Equipment Industry Association is an industry organization made up of toilet equipment manufacturers that handle products such as sanitary fixtures (large and small toilets) and warm-water washing toilet seats.
The Japan Sanitary Equipment Industry Association operates the JAPAN TOILET INFORMATION website, which is dedicated to providing information on toilet conditions in Japan (usage, signage, etc.) for foreign visitors to Japan.
(https://www.sanitary-net.com/utsukushitoilet/en/ )

[ Member Companies (As of June 2022, in alphabetical order) ]

Aisin Corporation, Asahi Eito Co., Ltd., Janis Ltd., Lixil Corporation, Panasonic Holdings Corporation, SAN-EI Faucet Mfg Co., Ltd, Toshiba Lifestyle Products & Services Corporation, TOTO Ltd.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye